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Pediatric lymphoid leukemia has the highest cure rate of all pediatric malignancies, yet due
to its prevalence, still accounts for the majority of childhood cancer deaths and requires
long-term highly toxic therapy. The ability to target B-cell ALL with immunoglobulin-like
binders, whether anti-CD22 antibody or anti-CD19 CAR-Ts, has impacted treatment options
for some patients.The development of new ways to target B-cell antigens continues at rapid
pace. T-cell ALL accounts for up to 20% of childhood leukemia but has yet to see a set of
high-value immunotherapeutic targets identified.To find new targets forT-ALL immunother-
apy, we employed a bioinformatic comparison to broad normal tissue arrays, hematopoietic
stem cells (HSC), and mature lymphocytes, then filtered the results for transcripts encoding
plasma membrane proteins. T-ALL bears a core T-cell signature and transcripts encoding
TCR/CD3 components and canonical markers of T-cell development predominate, espe-
cially when comparison was made to normal tissue or HSC. However, when comparison
to mature lymphocytes was also undertaken, we identified two antigens that may drive, or
be associated with leukemogenesis;TALLA-1 and hedgehog interacting protein. In addition,
TCR subfamilies, CD1, activation and adhesion markers, membrane-organizing molecules,
and receptors linked to metabolism and inflammation were also identified. Of these, only
CD52, CD37, and CD98 are currently being targeted clinically. This work provides a set of
targets to be considered for future development of immunotherapies for T-ALL.
Keywords: immunotherapy, chimeric antigen receptors, antibody therapy, adoptive immunotherapy, pediatric
leukemia,T-ALL,TALLA-1, HHIP
INTRODUCTION
The origin of leukemia may be best understood through the spe-
cific genomic mutations that alter the regulation, growth, and
differentiation of the lymphocytic cells that comprise the disease.
These mutations both define the biology of the disease at pre-
sentation and can also reveal the genetic origins of the leukemic
stem cell. The promise of next-generation sequencing technolo-
gies to more fully describe these mutations is starting to be fulfilled
as exomic or genomic sequencing has begun to supplement and
may someday replace traditional methods of leukemia diagno-
sis and classification based on pathology, immunophenotyping,
and molecular cytogenetics (including FISH, fluorescence-based
in situ hybridization, and PCR, polymerase chain reaction, for
known genetic lesions) (1).
Genomic technology, however, cannot stand on its own as ver-
ification of target expression is still required at the protein level.
Thus, it is immunophenotyping that ultimately informs the field
of immunotherapeutics whether or not a genetic target could serve
as therapeutic target for either antibody or T-cells transduced
to express chimeric antigen receptors (CAR-Ts). The advent of
CD19–CAR-T-cell therapy has impacted the treatment of pre-B-
cell ALL for some patients with advanced disease. Indeed, we and
others have proposed a number of targets that may be suitable
for pediatric B-ALL (2, 3). However, attractive targets for T-cell
leukemia have yet to be recognized and exploited. We present here
potential targets for treating T-cell ALL with antibody or CAR-
Ts, using strategies developed for the analysis of pediatric solid
tumors and B-ALL (4).
In 1993, Pui et al. reviewed ontogeny marker expression in T-
ALL in light of normal T-cell antigen expression during thymic
development (5). T-ALL was considered as either prothymocyte-
(expressing CD7), early thymocyte- (expressing CD5, CD2, and
CD1), intermediate thymocyte- (CD1, CD4, or CD8), or mature
thymocyte-like (CD3 and TCR surface expressed). The CD1 anti-
gen, expressed on cortical thymocytes, Langerhans cells, and a
subset of B-cells, is the only one of these developmental antigens
to be turned off upon reaching T-cell maturity. Reinherz originally
proposed that T-ALL be classified along the lines of CD1 and CD3
expression with stage I (early thymocyte) expressing CD2, CD5,
CD7, and no CD1, CD4, CD8, or CD3; stage 2 (intermediate)
expressing CD1, CD2, CD5, and CD7 with variable 4 and 8, and
weak CD3; and stage 3 (mature) expressing CD2, CD3, CD5, CD7,
and CD4 or CD8 (usually only one or the other) (6, 7). In most
simplistic terms, mature or medullary T-ALL expresses surface
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CD3, but not CD1a. Cortical or thymic T-ALL expresses CD1a,
but not surface CD3; and early T-cell precursor T-ALL (ETP-ALL,
which encompasses Pro-T-ALL and Pre-T-ALL) does not express
CD3 or CD1a.
The answer to the challenge of finding T-cell restricted targets
(that is a mature T-cell antigen present on ALL that can be safely
eliminated, as CD19 for B-cells), or a more T-ALL restricted target
(especially for the more immature forms of the disease) may lay
in the nature of the progenitor cell itself. As elegantly presented
by the St. Jude – Washington University Pediatric Cancer Genome
Project, early precursor T-cell ALL shares many similarities to dou-
ble negative thymocytes that have the potential to differentiate into
cells of either T-cell or myeloid lineage (8, 9). This pluripotency
makes the antigenic expression profile for T-ALL far more gener-
alized. At the other end of the spectrum, the most mature forms of
T-ALL may benefit from new immunotherapeutic approaches that
target the T-cell receptor, specifically, different subclasses that have
clonally expanded. Although this was once deemed an approach
to be of little interest due to the low number of cases, and the
need for an almost individualized treatment approach, the suc-
cess of CAR-T-cell therapy, which is the essence of personalized
or individualized medicine, has brought this approach to the fore
once more.
DATA INTERROGATION AND RESULTS
T-cell ALL (acute lymphocyte/lymphoblastic leukemia) accounts
for 15–18% of all childhood leukemias and 25% of ALL in adults
(5, 10). However, we have yet to see a set of high-value targets
proposed for T-cell ALL as we have for B- or pre-B-ALL. To that
end we undertook a bioinformatics approach to describe the cell
surface proteins expressed on T-ALL. Although we have begun to
accumulate and analyze T-ALL cases at the Pediatric Oncology
Branch of the NCI, a large data set was recently made available at
Gene Expression Omnibus (GEO) using the Affymetrix Human
Genome U133 Plus 2.0 platform. In this submission, GSE47051,
over 100 cases of pediatric T-ALL and pre-B-ALL are available for
analysis. The samples were of high quality and derived from bone
marrow or peripheral blood aspirates of pediatric ALL patients
enrolled in two co-operative group trials (NOPHO, Nordic Society
for Pediatric Hematology-Oncology), fully described in the origi-
nal publications for this sample set (11, 12). Samples were obtained
under informed consent, approved by the Regional Ethical Board
in Uppsala, Sweden, and in accordance with the guidelines set forth
in the Declaration of Helsinki.
By navigating to the GEO home page, the CEL files for these
annotated samples were accessed and analyzed. To test the accuracy
of the pathological categorization of this sample set, we carried
out hierarchical clustering using the freely available ArrayMining-
tool (Online Microarray Data Mining Tool)1 (13). In Figure 1 we
demonstrated the partitioning of the pre-B-ALL and T-ALL sam-
ples, confirming their original pathological classification. More-
over, the genes driving this classification are unmistakably well-
recognized components of ALL, Table 1. The T-ALL set contains
CD3D, CD7, and CD28; while in the pre-B-ALL set we find CD19,
1http://www.arraymining.net
CD79B, and CD22. In Table 1 we present the top 10 cell surface
genes with regard to Pearson correlation (gene vs. outcome), and
in Figure 2, we present the top four overall scores, as expressed by
their respective sample sets. Not surprisingly, the gene expression
values that drove this classification were highly divergent from
each other, such as CD3D for T-ALL and CD19 and EBF1 (early
B-cell factor 1) for pre-B-ALL. Having confidence in the submitted
sample classification, we then analyzed the T-ALL and pre-B-ALL
samples for differences in average gene expression in comparison
to broad normal tissue arrays. For each cell surface membrane
transcript, an average expression level was calculated, and then
compared to the average expression of the transcript in normal
tissue, thus defining a potential space for immunotherapeutic
intervention. Methods for this analysis were published previously
(4). To confirm our analysis, we also analyzed normal and disease
gene expression files using the Partek® Genomics Suite™ v6.5. The
GEO database was used to download individual CEL files into the
software suite, and data analyzed for quality, differential expres-
sion, and with statistical packages for differential gene expression
(14–16).
Table 2 lists the top 40 genes for each disease category, as a
function of the ratio of an individual transcript’s expression level
in ALL vs. a set of 117 normal tissues, our broad normal tissue
array. A third of the transcripts (15 of the 46 transcripts, 33%)
were present in both pre-B-ALL and T-ALL. These transcripts
are by definition shared more between the two leukemias than
with normal tissue. They are (bold italics in the table): PTGER4,
ITGA4, CD37, CD52, CD62L (L-selectin), CXCR4, CD69, EVI2B
(CD361), SLC39A8, MICB, LRRC70, CLELC2B, HMHA1, LST1,
and CMTM6 (CKLFSF6).
SHARED PRE-B-ALL AND T-ALL GENES
SLC39A8 is the easiest to classify as this zinc transporter is a
solute carrier protein expressed during inflammation. In short,
it is a response to metabolic demand (17). The next group of
markers that naturally fall together has to do with core hom-
ing and adhesion functions of lymphocytes, specifically CD37,
a tetraspanin that associates with integrins; CD49d, an integrin
expressed on activated lymphocytes; CD62L, a homing recep-
tor; CD52, an adhesion receptor; CXCR4, whose natural ligand
is SDF-1 and mediates homing to the bone marrow. Tetraspanins
organize plasma membrane domains in order to co-ordinate sig-
naling and cellular functions. In B-cells, the CD81/CD21/CD19
co-receptor complex interacts with CD82 and lipid rafts, while
in T-cells the CD151/CD81/CD37/Tssc-6 complex is thought to
perform a similar structural-signaling role (18, 19). This link-
age to the tetraspanin CD37 is significant, as our data now
link the expression of CD37 with known adhesion receptors
of the integrin family in ALL. Anti-CD37 antibody is cur-
rently being evaluated in adult B-cell malignancies (NHL, CLL,
MM, ALL) as a drug conjugate with the maytansine derivative
DM1 (20).
CXCR4 is over-expressed in more than 20 different cancers,
and expression in normal tissues (other than in the CD34 stem
cell niche in bone marrow) is measurably lower (21–23). CD49d
(alpha 4, beta 1/beta 7 integrin) is an adhesion receptor that medi-
ates both rolling and firm adhesion to endothelium (24). CD49D
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FIGURE 1 | Hierarchical clustering ofT-ALL and pre-B-ALL.
Samples from GEO data set GSE47051 were downloaded and then
clustered without reference to their diagnostic category (T-ALL or
B-ALL). The top genes driving the subsequent clustering are listed in
the x -axis, and the disease categories of those samples on the
y -axis. Gene expression (log2cs) was normalized by z score
(x -mean/std.dev.) across all leukemia samples for purposes of
comparison.
expression in tandem with CXCR4 has been studied in pediatric
and adult ALL. In children with ALL, no difference in expression
levels was correlated to outcome, while adults with high CXCR4
and low CD49D (VLA-4) did worse (25).
CD62L is the canonical homing receptor for lymphocytes to
enter secondary lymphoid tissues via high endothelial venules.
Recently, targeting CD62L has been proposed for CLL, and thus
it may be a viable target in pediatric ALL (26). CD52 is the
well-characterized target of the anti-CAMPATH-1 antibody alem-
tuzumab, and is expressed on activated T-cells. This represents
a second opportunity to more fully explore in pediatric ALL.
CLEC2B (C-type lectin domain family 2B), is encoded in the
NK cell killer gene complex on chromosome 12, and is also
known as activation induced C-type lectin of T-cells, called AICL
(27). AICL/CLELC2B map adjacent to CD69 whose C-type lectin
domain is similar in sequence. CD69, a well-described activation
marker for T-cells has also been found to be valid marker for prog-
nosis in CLL, reflecting its ability to be up-regulated in either cell
lineage (28). MICB (MHC class I polypeptide-related sequence
B), is a ligand for NKG2D, and it thus activates T or NK cells. The
shedding of the MICB protein is thought to help tumors evade NK-
mediated immunosurveillance (29). Although not expressed on
pre-B-ALL, CD96 is also an immunoglobulin superfamily mem-
ber, and we discuss it here because it is also a ligand for activated
T or NK cells. CD96 has also been described as a leukemia stem
cell marker in AML (30). Since the expression of CD96 is low
or absent on normal hematopoietic stem cells (HSC), Staudinger
et al., have proposed using anti-CD96 antibody to purge bone
marrow during hematopoietic stem cell transplantation (HSCT)
for the disease (31).
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Table 1 |Top 10 cell surface genes driving classification.
Identifier Gene name Description PC Fold-change
SURFACET-ALL MARKERS
213539_at CD3D CD3d molecule, delta chain of TCR/CD3 0.97 53.6
214551_s_at CD7 CD7 molecule 0.94 17.95
205456_at CD3E CD3e molecule, epsilon chain of TCR/CD3 0.93 17.52
226246_at KCTD1 K channel tetramerization domain containing 1 0.92 7.87
211796_s_at TRBC2 T-cell receptor beta constant 2 0.91 61.21
226245_at KCTD1 K channel tetramerization domain containing 1 0.91 10.55
206545_at CD28 CD28 molecule 0.91 27.11
227236_at TSPAN2 Tetraspanin 2 0.9 10.94
217147_s_at TRAT1 TCR-associated transmembrane adaptor 1 0.89 28.59
220253_s_at LRP12 LDLR-related protein 12 0.88 9.55
SURFACE B-ALL MARKERS
206398_s_at CD19 CD19 molecule −0.96 0.03
226878_at HLA-DOA MHC class II, DO alpha −0.92 0.07
205297_s_at CD79B CD79b molecule, Ig-associated beta −0.9 0.07
228831_s_at GNG7 G-protein, gamma 7 −0.9 0.07
209374_s_at IGHM Immunoglobulin heavy constant mu −0.89 0.06
223533_at LRRC8C Leucine-rich repeat containing 8 family, C −0.89 0.11
220068_at VPREB3 Pre-B lymphocyte 3 −0.89 0.02
38521_at CD22 CD22 molecule −0.88 0.24
207857_at LILRA2 Leukocyte ig-like R, subfam. A (w/TM domain), 2 −0.87 0.06
217478_s_at HLA-DMA MHC, class II, DM alpha −0.87 0.05
Genes were clustered, and then ordered according to Pearson correlation co-efficient (PC, gene vs. outcome). The genes scoring as a positive (T-ALL markers) or
negative (B-ALL markers), confirm the original designation in GEO.
FIGURE 2 | Gene expression values, across all samples, for top
scoring hits. The average and range of values of the top four genes are
presented in this box and whisker plot, demonstrating that CD3D and
CD7 for T-ALL and CD19 and EBF1 for BCP-ALL (B-ALL) can be used to
readily distinguish and verify the original pathological classification of
these disease samples.
CD361 (EVI2B) is a recently described antigen that was clas-
sified in 10th human leukocyte differentiation antigens (HLDA)
conference as part of the B-cell panel, showing specific staining
of ALL (32). This gene is found in an intron of the NF1 (neu-
rofibromatosis type 1) gene, along with EVI2A and OMpg, being
transcribed in the opposite direction from NF1 (33). Little is
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Table 2 |T-ALL and B-ALL cell surface immunotherapy targets.
T-ALL vs. normal tissue B-ALL vs. normal tissue
Rank
(T)
Fold-
change
Symbol Comment Affy ID Rank
(T)
Fold-
change
Symbol Comment Affy ID
1a 97.6 TCRBV5-4 TCR beta chain 211796_s_at 1 90.8 CD69 209795_at
2 67.5 CD3D CD3-delta 213539_at 2 83.3 VPREB1 Pre-B lymphocyte 1 221349_at
3 64.9 PTGER4 Prostaglandin E, R4 204897_at 3 57.3 CD52 34210_at
4 60.8 CD69 209795_at 4 53.9 IGHM Ig HC-M 212827_at
1b 56.7 TRBC1 TCR beta chain 210915_x_at 5 44.3 CXCR4 217028_at
1c 48.9 TCBC1/BV19 TCRB 213193_x_at 6 43.1 IGGL1 Surrogate light chain 206660_at
5 39.4 ITGA4 CD49d 213416_at 7 39.7 CD24 208650_s_at
6 36.7 CD52 34210_at 8 35.4 VPREB3 220068_at
7 35.3 CD1E 215784_at 9 34.9 LILRA2 207857_at
1d 28.6 TCRDC TCR delta constant 216191_s_at 10 27.7 EVI2B 211742_s_at
8 26.1 SELL CD62L/selectin L 204563_at 11 26.9 MME CD10/CALLA 203434_s_at
9 25.6 CD28 206545_at 12 26.7 PTGER4 204897_at
10 24.6 CXCR4 217028_at 13 23.4 ITGA4 213416_at
11 23.1 EVI2B CD361 211742_s_at 14 22.0 CD79A 205049_s_at
12 20.9 SLC39A8 Zinc transporter 209267_s_at 15 21.7 CD79B 205297_s_at
13 20.2 ICAM-3/CD50 204949_at 16 18.1 CLEC2B 209732_at
14 19.6 PTPRC CD45R 212588_at 17 16.9 SLC39A8 209267_s_at
15 17.1 CD96 206761_at 18 16.7 CD19 206398_s_at
16 16.4 CD7 214551_s_at 19a 16.7 HLA-DRA MHC class II 208894_at
17 15.3 ITGAL/CD11a 1554240_a_at 20 16.7 MICB 206247_at
18 14.4 MICB Ligand for NKG2D 206247_at 21 14.7 LRRC70 238488_at
19 13.0 LRRC70 SLRN 238488_at 19b 14.2 HLA-DQ1 212671_s_at
20 13.0 CD2 205831_at 22 14.2 PAG1 225622_at
21 12.6 CD3E CD3-epsilon 205456_at 23 13.0 LILRB2 210146_x_at
1e 12.4 TCRG2 TCR gamma C 2 213060_s_at 24 12.8 CD58 211744_s_at
22 12.2 CLEC2B C-type lectin 209732_at 25 12.3 CD37 204192_at
23 11.6 CD247 TCR zeta chain 210031_at 26 12.3 HMHB1 208302_at
24 11.4 IL2RG CD132 204116_at 27 11.1 FLT3 206674_at
1f 11.2 TCR delta 213830_at 28 10.4 CD72 215925_s_at
25 11.0 CD1B 206749_at 29 10.3 CD53 203416_at
26 11.0 CD3G CD3 gamma 206804_at 30 10.2 LRR8C 223533_at
27 10.6 P2RY8 229686_at 19c 10.1 HLA-DPA1 211991_s_at
28 10.4 HMMR RHAMM/CD168 207165_at 31 9.8 FAIM3 FcR for IgM 221601_s_at
29 10.2 CD37 204192_at 32 9.7 CMTM7 CKLFSF7 226017_at
30 10.2 CD99 201028_s_at 33 9.6 TLR1 CD281 210176_at
31 10.2 HHIP 1556037_s_at 34 9.5 MS4A1 228592_at
32 8.5 IL-7R 226218_at 35 9.1 LST1 214181_x_at
33 8.5 LST1 214181_x_at 19d 9.1 HLA-DMA 217478_s_at
34 8.3 PTPRCAP CD45AP 204960_at 36 8.7 IGHD 213674_x_at
35 7.8 HMHA1 Minor HA-1 212873_at 37 8.4 CMTM6 217947_at
36 7.5 LPAR6 Lysophosphatidic acid R 218589_at 38 8.3 CD97 237510_at
37 7.1 ORAI2 Ca++ channel modulator 217529_at 39 8.1 MHMA1 212873_at
1g 7.0 TCRGC 2 211144_x_at 40 7.9 MILR1 217513_at
38 6.9 CD84 244352_at 41 7.9 ICAM-3 204949_at
39 6.8 TSHR 215442_s_at 42 7.7 SELL 204563_at
40 6.8 CMTM6 CKLFSF6 217947_at 43 7.5 LY9 CD229 231124_x_at
The left hand side of the table lists the top scoring hits forT-ALL, and the right side of the table shows the top hits for pre-B-ALL, expressed as the ratio of expression in
the leukemia over the expression of that transcript in normal tissue (117 samples covering all major tissue types of the body). These values were calculated using the
ANOVA module in PartekGenomics Suite (Partek, Inc., St. Louis, MO, USA), where T tests, ratio of average expression, and the associated p values were calculated.
Rank, indicates the numerical order list, with the TCR subunits for T-ALL and the MHC class II genes for B-ALL marked with a letter so as to indicate the presence
of very similar hits. The affy ID generating the highest scoring hit is reported, and hits for identical genes were not repeated. The comment column is used to report
alternate nomenclature. Boxes are used to indicate genes we have previously described as over-expressed in B-ALL (4). Gene symbols in bold italic are present in
both T-ALL and B-ALL lists. The highest p value for all the analyses presented in this table was 2.2×10−30, and thus p values are not presented in the table.
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known of its function, and it may be over-expressed simply
because of its genomic location. The CMTM6 (CKLF-like MAR-
VEL transmembrane containing 6, CKLFSF6) is a chemokine-like
gene that also contains a domain that bears sequence similar
to tetraspanins. Thus, it appears to play both a signaling and a
membrane-organizing role. The biological function is still being
investigated.
LRRC70 (leucine-rich repeat containing 70/synleurin), is also
not well-described and may play a role in cell adhesion or may bind
a growth factor (34). Few functional studies have been carried out
on the LRR protein family. PTGER4, is a prostaglandin receptor.
This G-protein-coupled receptor is known to activate T-cells. Lym-
phocytic colitis was recently shown to be associated with increased
TNFA, IFNG, and PTGER4, and a role for prostaglandin pro-
posed in activating pathogenic lymphocytes (35). LST1 (leukocyte
specific transcript 1) is expressed normally in cells of myeloid lin-
eage, serving as transmembrane adaptor protein, interacting with
the SHP-1 and SHP-2 phosphatases (36). There is no described
association with LST1 and ALL to this point.
Mutis et al., generated cytotoxic T-cells restricted to the non-self
HLA molecule HA-1/MMHA1 (histocompatibility, minor, HA-1),
and proposed using this reactivity to actively target residual dis-
ease during HSCT (37, 38). The restriction of this antigen to the
hematopoietic system highlights the fact that HSCT, which is often
part of ALL therapy, could be augmented by targeting leukemia-
expressed HA-1. In clinical trials, HA-1 and HA-2 peptide vaccines
are being tested for the induction of increased graft vs. leukemia
effect following allogeneic HSCT (NCT00943293). In reviewing
this list of genes over-expressed in both T-ALL and pre-B-ALL, in
comparison to normal tissue, a general picture of immune activa-
tion arises. While some of the proteins encoded by the transcripts
expressed by both T-ALL and B-ALL are not as well-characterized,
they still fit this theme and are also likely to be expressed through-
out the immune system. Obvious therapeutic correlation can be
made for CD52 and CD37. Antibody to CD96 is used for purging
marrow, because it is too broadly expressed in normal tissue to be
targeted by an active agent. The ability of MICB and CD96 to acti-
vate T-cells or NK may also be an important insight, as adoptive
immunotherapy with T-cells engineered to express NK ligands has
been demonstrated and their presence may therefore be associated
with an activated mature phenotype (39). Also of importance to
immunotherapy is the presence of minor antigen (HA-1) in ALL
that may be exploited during HSCT. We now turn our attention
to the transcripts expressed in the disease most in need of new
approaches, pediatric T-ALL.
T-ALL GENES
Among the T-ALL transcripts listed as being over-expressed
in Table 2, 7 of 46 are TCR chains (TCRBV5-4, TCRBC1,
TCBC1/TCRBV, TCRDC, TCRG2, TCR delta, and TCRGC2) and
4 are members of the CD3 complex (CD3-delta, -epsilon, -gamma,
and -zeta), making 11 of 46 (23%) of the T-ALL hits in Table 2
directly related to clonotypic T-cell marker expression. This analy-
sis does not inform us directly if these molecules are on the
surface, as the presence of the surface protein CD3-epsilon is
the key diagnostic criterion for classification of T-ALL as being
mature/medullary type, but many of these are re-arranged TCR
chains indicating the T-ALL data set we are analyzing is weighted
toward a more mature phenotype. Thinking of these re-arranged
proteins as immunotherapeutic targets will be discussed later.
Transcripts for many canonical normal T-cell markers are
also seen in T-ALL: such as, CD2, CD7, CD11a, CD28, CD45R,
CD45AP, CD84, CD99, IL2RG, IL-7R, and the CD1 family mark-
ers CD1E and CD1B. If we consider this set of transcripts as an
aggregate diagnostic of a single case, the presence of CD2 and CD1
transcripts, along with CD7 would classify this sample as a corti-
cal or thymic T-ALL, which is in keeping with the predominance
of re-arranged TCR transcripts detected (as opposed to an early
T-cell precursor type ALL). CD84 is in the SLAM (signaling lym-
phocyte activation molecule) subset of the CD2 family of proteins,
and mediates T-cell activation through homotypic adhesion (40).
CD28 is the well-characterized second signaling molecule,CD11A
(LFA-1 alpha chain) is a well-recognized lymphocyte integrin, and
CD45 is LCA (leukocyte common antigen). CD45AP is known to
positively regulate CD45 function. The transcripts for IL2 and IL7
receptor chains are also in keeping with the T-cell transcriptome
of T-ALL. CD99 is a well-characterized marker of T-ALL and in
pediatric disease its high level of expression has been proposed as
a marker for detecting minimal residual disease along with CD3,
CD7, and/or TdT (41). Hence, this set of transcripts is largely a
picture of a normal activated immune cell.
The expression of CD1A is a key diagnostic for T-ALL, repre-
senting the key transition, along with high expression of CD2, to a
more mature phenotype. In our analysis, we detected transcripts
for CD1B and CD1E. CD1A is thought to be the primary cell sur-
face CD1 family member while CD1B interacts with intracellular
lipids and CD1E functions as a lipid chaperone, reviewed in Ref.
(42). Nevertheless, CD1B clearly presents mycobacterial antigens
to T-cells and is on the surface (43). In studying LEF1 mutations
in pediatric T-ALL, Gutierrez et al. demonstrated that this sub-
set of pediatric T-ALL was arrested at the cortical stage and they
demonstrated the presence of CD1B and CD1E by gene expres-
sion profiling (44). We can infer from this that the CD1 family
is induced as a group, and also hope that unique subsets of lipid
antigens may be present on T-ALL. None have yet been reported.
Three immune cell adhesion receptors are over-expressed in
T-ALL. ICAM-3 (CD50) is constitutively expressed on most B-
cell malignancies, except for Hodgkin lymphoma, and myeloid
cells, but appears to be absent from other tissues, with the possi-
ble exception of tumor-associated vasculature (45, 46). We report
here that it is likely to be found on pediatric T-ALL as well.HMMR
(hyaluronan-mediated motility receptor, RHAMM, or CD168), is
found in a complex containing BRCA1 in breast tissue where it may
govern apicobasal polarity (47). TCRs recognizing RHAMM were
generated in a model system and found to inhibit AML growth in
a xenogeneic system (48). However, these T-cells also recognized
CD34+ HSC in an HLA-A2 restricted manner. Thus, an active
T-cell population targeting HMMR could only be envisioned for
clinical use in an HLA mismatch setting.
LPAR6, lysophosphatidic acid receptor 6, is another interest-
ing transcript that may be expressed either for its contribution
to cellular transformation or it may be part of an active genomic
locus, as it is transcribed from an intron of the RB gene (49).
On its own, this G-coupled receptor is known to stimulate cell
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activation upon encountering its ligand, lysophosphatidic acid,
and may play a role in tumor cell tissue invasion (50). Like the
zinc transporter, another T-cell metabolic protein, ORAI2 (ORAI
calcium release-activated calcium modulator 2) is over-expressed
in T-ALL. It is likely to function in a manner similar to ORAI1
where STIM1 activates the translocation of this calcium channel
to the surface of the T-cell upon depletion of intracellular calcium
stores (51).
Three transcripts expressed by T-ALL are a little more enig-
matic, but reflect the fact that we are dealing with a transformed
cell population. HHIP (Hedgehog interacting protein) interacts
with all forms of sonic hedgehog (SHH), a secreted factor that
guides tissue formation during development, and is a key medi-
ator of its function (52). HHIP function on T-ALL has not been
explored, but an AML study has described the ability of AML-
derived stromal cells to express HHIP and to interact with AML
stem cells that now re-express SHH and its receptor, smoothened
(SMO) (53). TSHR (thyroid stimulating hormone receptor) is
not normally considered a T-cell antigen, but mutations of this
receptor have been associated with increased vasculature and
the development of pituitary adenomas (54, 55). Clinical studies
with TSHR primarily focus on Grave’s disease. P2RY8 (purinergic
receptor P2Y, G-protein-coupled 8), is best known as supplying
the promoter that drives CRLF/TSLPR overexpression, upon dele-
tion of an intervening pseudoautosomal region, in certain cases of
B-ALL (56, 57). In a fascinating study, Fujiwara et al., screened for
transforming genes in the rare biphenotypic acute leukemia (BAL),
which bears both lymphoid and myeloid markers (58). They found
P2RY8 expression to activate a number of cellular activation path-
ways, including those mediated by CERB and Elk-1. Thus, P2RY8
may be over-expressed simply by residing in a very active genomic
region or it may play a functional role in transforming leukemia
cell clones.
In order to further analyze T-ALL gene expression signatures,
we sought to determine if the normal gene sets we used for
comparison had an impact on the type of transcripts identified
as being over-expressed. We ran two subsequent analyses using
CD34+ bone marrow-derived HSC, and normal peripheral blood
mononuclear cells, as the normal tissue comparators, Table 3. HSC
CEL files were submitted by Dehashis Sahoo to GEO as GSE32719
by the Weissman Lab at Stanford University, USA (59). We selected
CD34+ HSC that was from normal donors aged 19–31 years old
(n= 14). For normal PBMC, we used control patients from the
GEO Submission GSE21942 by Kemppinen and Saarela at the
University of Cambridge, UK (n= 15) (60). In the top half of
Table 3, where comparison is made to HSC, a profile similar to
the normal tissue array of Table 2 is seen, where T-cells tran-
scripts predominate. In fact 60 and 70% of the transcripts (ranked
by T score and fold-change, respectively), were shared. However,
when comparison was made to PBMC, the percentage of shared
transcripts dropped to 10 and 15% for T score and fold-change,
respectively. Only three transcripts were shared between the lists
featured in the top and bottom half (HSC vs. PBMC) Table 3
shows CD3D (the delta chain of the TCR complex), HHIP, and
TALLA-1 (TSPAN7). The presence of T-cell associated like tran-
scripts has been discussed, but HHIP and TALLA-1 warrant special
attention.
In a series of papers in the 1980s, Seon et al. described a unique
human T-cell leukemia antigen identified by a monoclonal anti-
body, designated it TALLA (61, 62). Immunotoxin-conjugated
antibody to TALLA was found to control the growth of leukemic
xenografts in nude mouse models (63). The antigen, a tetraspanin,
is now referred to as TSPAN7, is expressed from the X chromo-
some, and has been most recently been explored with regard to
its role in differentiating glutamatergic neurons (64). As discussed
above, little is known about HHIP and leukemia. As HHIP is likely
to regulate stem cell-like characteristics of either leukemia cells, or
stromal cells that support them it should be considered a high-
value target (53). Also of interest was our detection of SLC7A5,
which is also known as CD98, in the T score but not fold-change
column of Table 3, where comparison is made to PBMC. A human-
ized monoclonal antibody to CD98, IGN523, is currently being
tested in refractory or relapsed AML (NCT02040506). CD98 is
composed of two chains, and has the ability to signal though both
mTOR and AKT pathways (65).
All of the gene expression data are presented in our fully
annotated Oncogenomics database2.
DISCUSSION
In seeking to analyze a series of pediatric malignancies for potential
immunotherapeutic targets, we did not have a data set sufficiently
robust to analyze pediatric T-ALL. In the data presented here,
we now can add T-ALL to our list of pediatric malignancies that
have been analyzed at the transcript level. Future studies will
be enhanced by our ability to look at next-generation sequenc-
ing data, and to perhaps identify differential expression between
tumor and normal at even finer levels, such as comparing alter-
native splicing profiles. Although we did not discuss our data for
pre-B-ALL in a transcript by transcript level, our results were con-
sistent with our earlier work looking at a more restricted set of
normal tissues (4). The antigens CD19, CD79A, CD79B, CD49d,
CD53, CD72, TLR1, and MILR1 were all reported previously.
Thus, our pre-B-ALL analysis sets are consistent. New and poten-
tially interesting hits that arose in this new analysis for B-ALL
include CD52, CD24, and CD10/CALLA. Therapeutic antibodies
have been developed for all of them.
The analysis of pediatric T-ALL is novel, and seems to reflect the
perplexing nature of this disease in that the majority of the over-
expressed transcripts are likely to be broadly expressed throughout
the immune system. Thus CD2, CD69, and CD99 are all very risky
targets that may require more sophisticated approaches than a sin-
gle antibody or CAR-T. This holds true for CD96 as well, which
is being used to purge bone marrow, but is too broadly expressed
to be targeted systemically. We do have some reasonable antigens
to target, but the data may be telling us something else. It may be
time to consider more fully the use of clonotypic antibodies or
targeted CAR-Ts to permanently eliminate specific T-cell subsets.
In the clinic, minimal residual disease can be detected in>95%
of ALL patients by PCR detection of patient-specific rearrange-
ments of the TCR or the immunoglobulin locus. This argues that
at a genetic level the TCR is a valid target for therapeutic devel-
opment (66). Campana et al. looked carefully at the expression
2http://home.ccr.cancer.gov/oncology/oncogenomics/
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Table 3 | Comparison ofT-ALL to HSC and PBMC normal gene expression profiles.
Rank Symbol Gene title T score Rank Symbol Gene title Fold-change
T-ALL VS. HSC
1 CD3D* CD3d molecule, delta 50.7 1 CD3D* CD3d molecule 140.1
2 CD3G* CD3g molecule, gamma 24.2 2 TRBC1* T-cell receptor beta constant 1 110.7
3 TRBC1* TCR beta constant 1 22.1 3 CD1E* CD1e molecule 54.6
4 CD99* CD99 molecule 20.8 4 TRDC* T-cell receptor delta constant 42.9
5 CD7* CD7 molecule 20.1 5 TRDV3 T-cell receptor delta variable 3 39.4
6 B2M Beta-2-microglobulin 18.6 6 CD2* CD2 molecule 39.2
7 CD96* CD96 molecule 17.2 7 CD28 CD28 molecule 31
8 IL2RG* Interleukin 2 receptor, gamma 17.0 8 CD3E* CD3e molecule, epsilon 28.6
9 CD3E* CD3e molecule, epsilon 16.9 9 CD7* CD7 molecule 26.6
10 LIME1 Lck interacting transmembrane adaptor 1 16.1 10 CD1B* CD1b molecule 26
11 CD46 CD46 molecule 16.1 11 HHIP* Hedgehog interacting protein 23.3
12 CD247* CD247 molecule 16.0 12 CD96* CD96 molecule 22.9
13 ITGB1 Integrin, beta 1, CD29 14.3 13 CD99* CD99 molecule 22.1
14 LAX1 Lymphocyte transmembrane adaptor 1 13.5 14 CD3G* CD3g molecule, gamma 21.2
15 ITGAE Integrin, alpha E, CD103 13.4 15 AQP3 Aquaporin 3 (gill blood group) 20.7
16 HHIP* Hedgehog interacting protein 12.9 16 IL-7R* Interleukin 7 receptor 20.5
17 ITM2A Integral membrane protein 2A 12.4 17 LPAR6 Lysophosphatidic acid receptor 6 18.5
18 CXCR4* Chemokine (C-X-C motif) receptor 4 12.2 18 CD8A CD8a molecule 18.5
19 CD28* CD28 molecule 12.1 19 IL2RG* Interleukin 2 receptor, gamma 18.1
20 IGHM Immunoglobulin heavy constant mu 12.1 20 PVRIG Poliovirus receptor rel. Ig domain cont 16.4
21 TSPAN7 Tetraspanin 7, TALLA-1 16.1
T-ALL VS. PBMC
1 TFRC Transferrin receptor (p90, CD71) 21.2 1 TSPAN7 Tetraspanin 7, TALLA-1 55.0
2 TSPAN7 Tetraspanin 7, TALL-1 19.8 2 HHIP* Hedgehog interacting protein 23.7
3 TBXA2R Thromboxane A2 receptor 19.5 3 HMMR* CD168 – RHAMM 12.8
4 CD3D* CD3d molecule, delta (CD3-TCR complex) 19.4 4 IGSF10 Ig superfamily, member 10 11.4
5 FAF1 Fas (TNFRSF6) associated factor 1 16.4 5 VANGL1 VANGL planar cell polarity protein 1 6.8
6 HHIP* Hedgehog interacting protein 14.6 6 TFRC CD71-transferrin receptor 5.3
7 SLC39A8 SLC 39 (zinc transp.), 8 14.5 7 TRO Trophinin 5.0
8 A1BG Alpha-1-B glycoprotein 14.2 8 CACNB3 Ca++ channel, volt.-dep., beta 3 sub 4.3
9 OTOP2 Otopetrin 2 13.4 9 MAGED1 Melanoma antigen family D, 1 4.2
10 ITGAE Integrin, alpha, CD103 13.3 10 CD3D* CD3d molecule, delta (CD3-TCR complex) 4.1
11 TMEM237 Transmem. prot. 237 (tetraspanin) 12.9 11 CHRNA5 Cholinergic R, nicotinic, alpha 5 4.1
12 TRO Trophinin 12.6 12 FAF1 Fas (TNFRSF6) associated factor 1 3.1
13 SLC22A7 SLC 22 (organic anion transporter), 7 12.5 13 PTK7 Protein tyrosine kinase 7 3.1
14 SLC7A5 CD98/amino acid transporter, light chain 12.2 14 A1BG Alpha-1-B glycoprotein 2.8
15 CACFD1 Ca++ channel flower dom. cont. 1 11.8 15 GPC2 Glypican 2 2.4
16 IGH Immunoglobulin heavy locus 11.1 16 LRRC37A3 Leucine-rich repeat containing 37, A3 2.2
17 TNFRSF21 TNF receptor superfamily, member 21 11 17 IGH Immunoglobulin heavy locus 2.2
18 VANGL1 VANGL planar cell polarity protein 1 10.8 18 MRC2 Mannose receptor, C-type 2 2.1
19 FGFR1 Fibroblast growth factor receptor 1 10.6 19 SCNN1A Na+ channel, non-volt.-gated 1 alpha sub 2.1
20 GPC2 Glypican 2 10.6 20 LGR4 Leucine-rich repeat cont. GPCR 4 1.9
As forTable 2, T-ALL gene expression profiles were compared to either CD34 (+) HSC (top half of table) or PBMC (bottom half of table). Data are reported and ranked
according to T score (left half of table) or fold-change (right half of table). Both Gene Symbol and Gene Title are given for each transcript. Those transcripts that are
represented inTable 2 (where comparison was to an array of normal tissues) are followed by an asterisk in the Gene Symbol column. Those transcripts appearing in
both the top and bottom half of the table are in bold, with gray shading.
of intracellular vs. membrane-expressed CD3 and of the TCR in
T-ALL (67). In a series of ALL where patients ranged in age from 6
to 65 (median age, 20), 11 of 40 showed CD3 and either TCRAB (9
of 11) or TCRGD (2/11) on the membrane. Cytoplasmic TCR was
detected in 12/40; while 17/40 had neither CD3 or TCR surface
expression. In a study of adult T-ALL associated with HTLV-1
infection in Japan, all samples expressed surface TCR, albeit with
a low fluorescence intensity (68). In this study, 7/12 patient sam-
ples expressed TCR on the surface on >95% of their blasts. Thus,
the disease association with differentiation status holds, and we can
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state that a third of all patients with T-ALL are likely to have surface
TCR. Unfortunately, our acuity in diagnosis of T-ALL according to
the degree of cellular progression along the T-cell developmental
pathway has not resulted in any useful differentiation of outcome
status, with the possible exception of a slightly better outcome for
CD10+ disease (69).
We propose a second method for targeting certain sub-types
of T-ALL that express a surface T-cell receptor. We hypothesize
that deletion of a specific family or sub-family of TCR-bearing
ALL, for example the TCRBV5-4 family that ranked the highest
of all differentially expressed genes in Table 2, would effectively
eliminate that leukemic clone. Using CART-Ts specific for a single
TCR family would result in only a partial depletion of normal T-
cells, and the physiological consequences with respect to induced
immunosuppression may be minimal. This is in contrast to current
CD19–CAR-T therapy for B-ALL, where the entire healthy B-cell
compartment is ablated. Alternatively, the generation of target lists,
such as we present here may be exploited in the future when a new
generation of immunotherapeutic agents where more than one
set of antigens is required to fully activate an effector T-cell-can be
developed. The creation of a treatment strategy for prostate cancer
that requires recognition of both PMSA and PSCA to fully trigger a
dual-engineered T-cell population may be one such approach (70).
Our next step will be to validate surface expression of the tran-
scripts described here by flow cytometry, and thus complement
gene expression data with the demonstrated presence of protein
that could be targeted on the surface of pediatric T-ALL.
Finally, we also explored the effect of altering the normal tis-
sue comparator from a collection of normal tissues throughout
the body, to two more restricted normal tissue sample sets. The
first of these was the CD34+HSC compartment in bone marrow.
As this is the tissue from which the leukemia arises, one might
anticipate that a more tumor-like set of transcript would be iden-
tified. However, the transcripts remained very much T lymphocyte
specific, and up to 70% of the transcripts were shared when com-
parison was made between T-ALL and normal HSCs (Table 2 vs.
Table 3). We did see a noticeably different set of transcripts identi-
fied when peripheral blood lymphocytes were used as the normal
tissue comparison. The T lymphocyte specific transcripts were
lost and a more generic tumor-like set of transcripts were noted.
Interestingly, the CD3-delta chain of the TCR complex remained
highly over-expressed in all comparisons, as did TALLA-1 (in 2 of
3) and HHIP (in 3 of 3). TALLA-1 has been described previously as
a T-cell leukemia specific antigen and our analysis confirms that
this is a high priority target worthy of further exploration (61).
Shared between all comparisons was HHIP. HHIP has been ele-
gantly described as a modulator of SHH signaling, adding another
level of regulation to the patched (PTC1) and SMO pathway that
modulates expression of Hedgehog (Hh)-regulated genes (52). A
report demonstrating participation of this pathway in regulating
myeloid leukemia supports further research into the role of HHIP
in lymphocytic leukemia (53). In conclusion, there may be no
single “correct” normal tissue to use as a comparator for gene
expression profiles from leukemia samples. Instead, we should
view each comparison as a means to identifying unique aspects of
leukemia-associated gene expression patterns. These approaches
highlight that general tissue comparisons yield results that reflect
the tissue of origin of the malignancy,as seen in Table 2,while com-
parison to similar tissues types (in this case mature lymphocytes)
reveals transcripts that are biased toward those that are associated
with tumorigenesis, Table 3. However, both types of targets are of
value, especially in the context of immunotherapy, where finding
tumor-specific antigens that spare the host from fatal toxicity is the
goal. If we restricted ourselves to the HSC or lymphocytic com-
parators in studying B-ALL, we would have missed antigens like
CD19 and CD22 that are currently being targeted in experimen-
tal trials. When an antigen is found in all comparator scenarios,
such as HHIP, it certainly warrants further investigation. This is
also the case for TALLA-1, although it may not differ sufficiently
from normal tissue. The antigens identified by using a broad tissue
sample are certainly valuable, but as discussed, must be evaluated
for the impact of targeting the normal tissues that may share these
antigens, such as mature T-cell subsets.
In the Pediatric Cancer Genomes project, a database of preva-
lent mutations found in pediatric cancers, including T-ALL is
being assembled3. Currently, this database is very useful for identi-
fying mutations, which differs from our analysis, focusing on gene
expression levels relative to normal tissue data sets. The largest
collection of T-ALL samples at the Pediatric Cancer Genomes
database is derived from ETP-ALL (9), and when this and other
datasets are explored more closely it is apparent that only a very
small minority of the genes identified are cell surface membrane
proteins, with one exception, IL-7R. We also identified in IL-7R
in T-ALL when HSC was used as a comparator in the fold-
change analysis (Table 3), and as hit number 32 in the comparison
run with our broad normal tissue panel (Table 2). This high-
lights again that different targets of interest will be identified
when different normal comparators are used. This also encourages
mining the “normal” T-cell developmental antigens we have iden-
tified for potentially harboring oncogenic mutations as well. The
entire data in our fully annotated (including membranous pro-
tein assignment) gene expression database where users can search
specific genes and compare gene expression between T-ALL, B-
ALL, HSC, PBMC, and a range of normal tissue are available at:
http://home.ccr.cancer.gov/oncology/oncogenomics/.
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